[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 514
1. Pollard RE, Reilly CM, Uerling MR, Wood FD, Feldman EC: Cross-sectional imaging characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988-2006). J Vet Intern Med; 2010 Jan-Feb;24(1):160-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-sectional imaging characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988-2006).
  • BACKGROUND: Pituitary tumors in dogs can be adenomas, invasive adenomas, or adenocarcinomas.
  • In people, invasive adenomas and pituitary adenocarcinomas carry a worse prognosis than adenomas.
  • HYPOTHESIS/OBJECTIVE: To identify differentiating features on cross-sectional imaging in dogs with pituitary adenomas, invasive adenomas, and adenocarcinomas.
  • ANIMALS: Thirty-three dogs that had computed tomography (CT) or magnetic resonance imaging (MRI) performed and a necropsy diagnosis of pituitary adenoma (n = 20), invasive adenoma (n = 11), or adenocarcinoma (n = 2).
  • RESULTS: Mean (+/- standard deviation) age for dogs with pituitary adenomas (10.6 +/- 2.9 years) was greater than that of those with invasive adenomas (8.3 +/- 2.7 years, P = .04).
  • Eighteen out of 20 (90%) dogs with adenomas had contrast-enhancing masses.
  • Mean adenoma height was 1.2 +/- 0.7cm.
  • Eight out of 20 (40%) adenomas were round and 8/20 (40%) compressed surrounding brain.
  • Eleven out of 11 dogs (100%) with invasive adenomas had contrast-enhancing masses.
  • Mean invasive adenoma height was 1.8 +/- 0.7 cm, which was significantly greater than adenomas (P = .03).
  • Clinical and imaging features were variable for 2 dogs with adenocarcinomas.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Invasive adenoma should be suspected if a dog with a pituitary tumor is <7.7 years of age and has a mass > 1.9 cm in vertical height.
  • Adenocarcinomas are uncommon and metastatic lesions were not seen with imaging.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925577.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


2. Han YD, Hong YK, Kang JG, Choi YJ, Park CH: Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. J Korean Soc Coloproctol; 2010 Oct;26(5):339-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
  • METHODS: Fifty colorectal adenomas and forty adenocarcinomas were investigated by using immunohistochemical staining for COX-2, VEGF and EGFR.
  • The correlations of COX-2, VEGF and EGFR with the grade of dysplasia, the size of the adenoma, and various clinicopathologic factors were studied.
  • COX-2 and EGFR showed correlations with adenomas rather than adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152137.001).
  • [ISSN] 2093-7830
  • [Journal-full-title] Journal of the Korean Society of Coloproctology
  • [ISO-abbreviation] J Korean Soc Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2998021
  • [Keywords] NOTNLM ; Adenocarcinoma / Colorectal carcinoma / Cyclooxygenase 2 / Endothelial growth factor receptor / Vascular endothelial growth factor
  •  go-up   go-down


3. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.
  • Furthermore, only very few data are available on CDX2 expression in normal pituitary gland tissue and/or pituitary adenomas.
  • MATERIAL AND METHODS: We investigated CDX2 expression in 28 normal pituitary glands, 75 pituitary adenomas of varying hormonal activity (including 7 invasive adenomas and 7 atypical adenomas) and 23 craniopharyngiomas (17 adamantinous and 6 papillary) in tissue microarrays.
  • RESULTS: None of the pituitary adenomas, craniopharyngiomas and normal pituitary glands showed expression of CDX2.
  • CONCLUSIONS: There is no evidence for that CDX2 might play a role in tumourigenesis, invasive growth or tumour recurrence of pituitary adenomas or in tumourigenesis of craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


Advertisement
4. Simeonov R, Simeonova G: Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas. Res Vet Sci; 2008 Dec;85(3):559-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas.
  • Stained cytological specimens from 7 canine anal sac gland adenomas and 11 canine anal sac gland carcinomas were analyzed by computer-assisted nuclear morphometry.
  • The study aimed to evaluate (1) the possibility of using nuclear cytomorphometry as an auxiliary diagnostic method to differentiate between canine anal sac gland adenomas and adenocarcinomas, and (2) the prognostic value of nuclear morphometry in canine anal sac gland adenocarcinomas.
  • The results indicated that (1) MNA, MNP, MND and NR could be used as effective auxiliary tools for differential diagnosis between canine anal sac gland adenomas and adenocarcinomas, and (2) MNA, MNP and MND are reliable prognostic indicators for canine anal sac gland adenocarcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457852.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Grady WM, Ulrich CM: DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut; 2007 Mar;56(3):318-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • [Cites] Mutat Res. 2000 May 30;450(1-2):139-53 [10838139.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):835-42 [10963127.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27851-7 [10878012.001]
  • [Cites] Mutat Res. 2001 Aug 22;495(1-2):103-15 [11448648.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):168-70 [12107837.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Oncology. 2002;63(4):393-7 [12417795.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3518S-3521S [12421880.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):320-3 [14973087.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):281-6 [15140540.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1089-93 [15452166.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702 [9671741.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1473-80 [15831531.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):781-9 [16708352.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [CommentOn] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • (PMID = 17339242.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059045; United States / NCI NIH HHS / CA / R01 CA114467; United States / NCI NIH HHS / CA / R01 CA59045
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 29
  • [Other-IDs] NLM/ PMC1856827
  •  go-up   go-down


6. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg; 2009 Aug;13(8):1510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
  • BACKGROUND: Mutations of KRAS are known to occur in periampullary and ampullary adenomas and carcinomas.
  • While oncogenic BRAF contributes to the tumorigenesis of both pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms/carcinomas (IPMN/IPMC), PIK3CA mutations were only detected in IPMN/IPMC.
  • This study aimed to elucidate possible roles of BRAF and PIK3CA in the development of ampullary and periampullary adenomas and carcinomas.
  • METHODS: Mutations of BRAF, NRAS, HRAS, KRAS, and PIK3CA were evaluated in seven adenomas, seven adenomas with carcinoma in situ, and 21 adenocarcinomas of the periampullary duodenal region and the ampulla of Vater.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2756-60 [7796400.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1875-8 [7753564.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):460-4 [8763258.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):91-5 [9247130.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):163-70 [16478646.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):34-46 [10579909.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):543-55 [11459270.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7420-5 [12032298.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1983-93 [12612072.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):272-8 [12640108.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):169-73 [12969789.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):305-10 [3972407.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • (PMID = 19440799.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701; United States / NCI NIH HHS / CA / CA127701-01A2; United States / NCI NIH HHS / CA / R01CA109525; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701-01A2; United States / NCI NIH HHS / CA / R21CA127701
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS164917; NLM/ PMC3915027
  •  go-up   go-down


7. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med; 2008 Sep 18;359(12):1207-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of CT colonography for detection of large adenomas and cancers.
  • The primary end point was detection by CT colonography of histologically confirmed large adenomas and adenocarcinomas (10 mm in diameter or larger) that had been detected by colonoscopy; detection of smaller colorectal lesions (6 to 9 mm in diameter) was also evaluated.
  • For large adenomas and cancers, the mean (+/-SE) per-patient estimates of the sensitivity, specificity, positive and negative predictive values, and area under the receiver-operating-characteristic curve for CT colonography were 0.90+/-0.03, 0.86+/-0.02, 0.23+/-0.02, 0.99+/-<0.01, and 0.89+/-0.02, respectively.
  • The per-polyp sensitivity for large adenomas or cancers was 0.84+/-0.04.
  • The per-patient sensitivity for detecting adenomas that were 6 mm or more in diameter was 0.78.
  • CONCLUSIONS: In this study of asymptomatic adults, CT colonographic screening identified 90% of subjects with adenomas or cancers measuring 10 mm or more in diameter.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] Radiology. 2005 Aug;236(2):519-26 [16040909.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):311-9 [12891530.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Br J Radiol. 2005 Jan;78(925):22-9 [15673525.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] J Periodontal Res. 1997 May;32(4):351-4 [9210088.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):517-21 [8623619.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):767-71 [15365402.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):631-8 [14975961.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):314-21 [15067626.001]
  • [CommentIn] Ann Intern Med. 2009 Feb 17;150(4):JC2-13 [19238611.001]
  • [CommentIn] Gastroenterology. 2009 Apr;136(4):1451-3 [19233331.001]
  • [CommentIn] N Engl J Med. 2008 Sep 18;359(12):1285-7 [18799563.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842-3; author reply 2843-4 [19115494.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2843; author reply 2843-4 [19115493.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842; author reply 2843-4 [19109581.001]
  • [ErratumIn] N Engl J Med. 2008 Dec 25;359(26):2853
  • (PMID = 18799557.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00084929
  • [Grant] United States / NCI NIH HHS / CA / CA080098-10; United States / NCI NIH HHS / CA / U01 CA080098; United States / NCI NIH HHS / CA / U01 CA080098-10
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS73206; NLM/ PMC2654614
  •  go-up   go-down


8. Cho EY, Kim KM, Park CK, Kim JJ, Sohn TS, Kim DW: AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas. APMIS; 2007 Jun;115(6):713-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
  • Alpha-methylacyl-CoA racemase (AMACR) is a novel tumor biomarker expressed in a number of neoplasms, including colorectal and prostatic adenocarcinomas.
  • Using immunohistochemistry we studied the expression of AMACR in normal gastric mucosa (n=32), intestinal metaplasia (n=26), adenomas (n=29) and adenocarcinomas (n=132) of the stomach from 135 patients.
  • Synchronous adenocarcinomas arising in the background of adenomas were observed in 26 cases.
  • Tissue from intestinal metaplasia, adenomas, and adenocarcinomas was positive in 7.7% (2/26), 79.3% (23/29), and 62.9% (83/132) of cases, respectively.
  • The difference in AMACR expression between adenomas or adenocarcinomas and non-neoplastic mucosa was statistically significant (p=0.0001).
  • Our results indicate that as well as being an additional diagnostic tool, altered AMACR expression in gastric adenomas and intestinal-type carcinomas suggests that AMACR may be involved early in the development of intestinal-type gastric carcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / analysis. Intestinal Neoplasms / metabolism. Intestines / pathology. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550379.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


9. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0%; mCEA, 0%; HER2/neu, 12%; mesothelin, 0%; loss of Dpc4, 0%) or BDH (CK20, 10%; p53, 0%; TAG-72, 0%; mCEA, 10%; HER2/neu, 0%; mesothelin, 0%; loss of Dpc4, 0%).
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • Although none of the BDA or BDH was positive for either p63 or AMACR, two of the metastatic pancreatic adenocarcinomas (8%) were positive for each of these peptides (P > 0.05).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology


10. Klosterman E, Colitz CM, Chandler HL, Kusewitt DF, Saville WJ, Dubielzig RR: Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas. Vet Ophthalmol; 2006 Nov-Dec;9(6):387-94
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas.
  • Ocular medulloepitheliomas, adenomas and adenocarcinomas share a common phenotype and originate from the optic cup neuroectoderm.
  • CK20 immunostaining was found in the adenomas but not in the adenocarcinomas or medulloepitheliomas.
  • AE1/AE3 expression was present more consistently in the adenocarcinomas and less frequently in the adenomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Adenocarcinoma / veterinary. Adenoma / diagnosis. Adenoma / immunology. Adenoma / veterinary. Animals. Dogs. Female. Immunohistochemistry / veterinary. Male. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / immunology. Neuroectodermal Tumors, Primitive / veterinary. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076871.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: [Human kallikrein 13 expression in salivary gland tumors]. Int J Biol Markers; 2006 Apr-Jun;21(2):106-110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas (ACC), polymorphous low grade adenocarcinomas (PLGA), acinic cell carcinomas (ACI), mucoepidermoid carcinomas (MEC) and adenocarcinomas not otherwise specified (ANOS) of both minor and major salivary glands were examined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207129.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS: Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci; 2010 Jul;55(7):1955-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.
  • Despite recent medical advancements, gastric adenoma or adenocarcinoma remains a considerable therapeutic challenge.
  • Endoscopic submucosal dissection (ESD) is a more recent approach that is now commonly used for radical resection of gastric adenoma and adenocarcinoma.
  • AIM AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and interleukin-6 (IL-6) are related to the prognosis of gastric adenocarcinoma.
  • However, the expression of these factors in gastric adenoma/adenocarcinoma following ESD has not been clearly evaluated.
  • Here, we report on our study of the expression of VEGF, EGFR, and IL-6 by immunohistochemical staining in extracted tissue from adenoma or adenocarcinoma of the stomach by ESD and subsequent evaluation of the correlation of VEGF, EGFR, and IL-6 with other clinicopathological parameters.
  • The patient cohort consisted of 102 patients with adenoma or adenocarcinoma of the stomach.
  • RESULTS: Immunohistochemical staining for VEGF and IL-6 was significantly higher in both high grade dysplasia and adenocarcinoma than in low grade dysplasia (P < 0.05).
  • Histological differentiation of adenocarcinoma was related to IL-6 expression (P = 0.028).
  • CONCLUSION: The immunohistochemical expression of IL-6 and VEGF can be considered to be useful for clinical diagnosis and follow-up of adenoma or adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Interleukin-6 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757047.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E: Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res; 2009 Sep-Dec;682(2-3):83-93
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes.
  • Surprisingly different frequencies and patterns of K-ras mutations are observed in human adenocarcinomas of the pancreas, colorectum and lung.
  • We evaluated all the available types of clinical and epidemiological studies on the relationship between tobacco smoking and the occurrence of K-ras mutations in human adenocarcinomas of the pancreas, colorectum and lung.
  • In pancreatic adenocarcinomas lifetime history of tobacco consumption was not significantly associated with the frequency of K-ras mutations (OR=1.26; 95% CI=0.82-1.94).
  • Similarly, no association was observed between smoking and K-ras mutations in colorectal adenocarcinomas (OR=0.94; CI=0.79-1.12), neither when colorectal adenomas and adenocarcinomas were jointly analyzed (OR=0.96; 95% CI=0.83-1.13).
  • In lung adenocarcinoma, where only 15-25% of cases harbor a K-ras mutation, tumors from smokers were more likely to have K-ras mutations than tumors from non-smokers (OR=3.67; 95% CI=2.47-5.45).
  • Furthermore, in lung adenocarcinomas K-ras mutations have a pattern different from that in pancreatic and colorectal adenocarcinomas.
  • In adenocarcinoma of the lung, smoking may play a role in the occurrence of K-ras mutations.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Pancreatic Neoplasms / genetics. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19651236.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 94
  •  go-up   go-down


14. Porjazova E, Zaprjanov Z, Milchev N, Markova D, Batashki I: [CDX2--an immunochystochemistry marker of intestinal differentiation of adenocarcinomas]. Akush Ginekol (Sofiia); 2009;48(4):32-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CDX2--an immunochystochemistry marker of intestinal differentiation of adenocarcinomas].
  • We present examination of CDX2 expression at 15 adenomas and 30 colorectal carcinomas.
  • All the adenomas are positive for CDX2, 27 /90%/ of the adenocarcinomas show nuclear expression of CDX2.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Intestines / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198783.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX1 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


15. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF: Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis; 2010 Jan;25(1):17-23
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas.
  • This study was to detect expressions of the two genes in colorectal adenomas and carcinomas and to analyze the correlation between Musashi-1 and beta1-integrin.
  • METHODS: Musashi-1 and beta1-integrin immunoreactivity was studied immunohistochemically in tissue microarray-based samples containing 69 colorectal adenocarcinomas, eight normal mucosa, and eight adenomas, and their messenger RNA (mRNA) expression level was detected by RT-PCR in resected specimens including the three types of tissue.
  • RESULTS: A percentage of 66.7% (46/69) and 59.2% (41/69) of colorectal adenocarcinomas were immunoreactive with Musashi-1 and beta1-integrin, respectively.
  • beta1-integrin expression was higher in group of adenocarcinomas than that of adenomas (P = 0.0276).
  • Significant differences of Musashi-1 and beta1-integrin mRNA expression levels were found between the normal colorectal mucosa, adenoma, and adenocarcinoma tissues (P = 0.01; P = 0.03, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Antigens, CD29 / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nerve Tissue Proteins / genetics. RNA-Binding Proteins / genetics. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714342.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / MSI1 protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


16. Klopfleisch R, Gruber AD: Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas. J Comp Pathol; 2009 Aug-Oct;141(2-3):113-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas.
  • Laser microdissected tissue samples were prepared from normal canine mammary gland and from simple adenomas, adenocarcinomas and their lymph node metastases.
  • Most adenomas displayed reduced expression of derlin-1 mRNA.
  • Few adenocarcinomas overexpressed derlin-1 mRNA, but all lymph node metastases overexpressed this gene product.
  • Stanniocalcin-1 mRNA was not expressed within adenomas and was reduced in adenocarcinomas and their lymph node metastases.
  • Taken together, these results suggest that malignant behaviour of canine mammary adenocarcinoma is associated with reduced transcription of the stanniocalcin-1 gene and overexpression of the derlin-1 gene.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / genetics. Glycoproteins / genetics. Mammary Neoplasms, Animal / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adenoma / veterinary. Animals. Biomarkers, Tumor / genetics. Dogs. Female. Gene Expression Regulation, Neoplastic. Microdissection / methods. Microdissection / veterinary. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Serpins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515379.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SERPIN-B5; 0 / Serpins; 76687-96-2 / teleocalcin
  •  go-up   go-down


17. Vorobiev GI, Tsarkov PV, Sorokin EV: Gasless transanal endoscopic surgery for rectal adenomas and early carcinomas. Tech Coloproctol; 2006 Dec;10(4):277-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gasless transanal endoscopic surgery for rectal adenomas and early carcinomas.
  • Histological examination revealed 112 adenomas, including 15 with neoplastic changes (6 cases of Tis and 9 cases of T1G1G2), 12 adenocarcinomas (1 case of Tis, 8 cases of T1G1G2, and 1 case of T2G1G2) and 3 carcinoid tumors.
  • Adenomas recurred in 9 patients (8.3%).
  • The adenocarcinomas demonstrated neither local recurrences nor distal spread.
  • GTES may be considered a safe and effective minimally invasive treatment for patients with large adenomas and early carcinomas of the rectum.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Laparoscopes. Proctoscopes. Proctoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Tech Coloproctol. 2009 Mar;13(1):103
  • (PMID = 17115311.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Tajika M, Nakamura T, Nakahara O, Kawai H, Komori K, Hirai T, Kato T, Bhatia V, Baba H, Yamao K: Prevalence of adenomas and carcinomas in the ileal pouch after proctocolectomy in patients with familial adenomatous polyposis. J Gastrointest Surg; 2009 Jul;13(7):1266-73
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of adenomas and carcinomas in the ileal pouch after proctocolectomy in patients with familial adenomatous polyposis.
  • However, adenomas may develop in the ileal pouch mucosa over time, and even carcinoma in the pouch has been reported.
  • Our aim was to evaluate the prevalence, nature, and etiology of ileal pouch and nonpouch adenomas and carcinoma in patients with FAP.
  • RESULTS: Sixteen of 24 pouch patients (Kock and IPAA) developed adenomas in the ileal pouch mucosa, and all patients with IRA developed adenomas in the rectal mucosa.
  • The prevalence of ileal adenomas was significantly higher in pouch patients than in IRA patients (P = 0.002).
  • Only one patient with Kock showed adenoma in the prepouch area.
  • Two cases of adenocarcinomas and one case of advanced adenoma were found in the ileal pouch mucosa.
  • CONCLUSION: Our results show a high frequency of adenomas in the ileal pouch mucosa, with evolution into carcinoma in some patients.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyposis Coli / surgery. Carcinoma / epidemiology. Colonic Neoplasms / surgery. Colonic Pouches / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333660.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Stolf BS, Santos MM, Simao DF, Diaz JP, Cristo EB, Hirata R Jr, Curado MP, Neves EJ, Kowalski LP, Carvalho AF: Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression. Cancer; 2006 May 1;106(9):1891-900
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression.
  • The majority of these nodules are benign, corresponding to goiters or adenomas, and only a small fraction corresponds to carcinomas.
  • Among thyroid tumors, the diagnosis of follicular adenocarcinomas by preoperative fine-needle aspiration biopsy is a major challenge, because it requires inspection of the entire capsule to differentiate it from adenoma.
  • METHODS: Using data from gene expression analysis, the authors applied Fisher linear discriminant analysis and searched for expression signatures of individual samples of adenomas and follicular carcinomas that could be used as molecular classifiers for the precise classification of malignant and nonmalignant lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / classification. Adenoma / classification. Thyroid Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565969.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • The poorly differentiated adenocarcinomas also exhibited coexpression of CK5 and p63.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


21. Brandizzi D, Carino S, Cabrini RL: Ploidy studies of pleomorphic adenomas and minor salivary gland carcinomas of the palate. Acta Odontol Latinoam; 2008;21(1):105-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ploidy studies of pleomorphic adenomas and minor salivary gland carcinomas of the palate.
  • The aim of the present study was to evaluate the DNA content of palate aggressive pleomorphic adenomas (PA) and adenocarcinomas of the salivary glands.
  • Six cases corresponded to aggressive pleomorphic adenomas (PA) and the remaining six to adenocarcinomas (AD).
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Pleomorphic / genetics. Neoplasm Invasiveness / genetics. Palate, Hard / pathology. Salivary Gland Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841754.001).
  • [ISSN] 0326-4815
  • [Journal-full-title] Acta odontológica latinoamericana : AOL
  • [ISO-abbreviation] Acta Odontol Latinoam
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


22. Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, Haruki T, Hamamoto Y, Shiomi T, Nakabayashi M, Ito H: Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer; 2010 Aug;13(3):177-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance.
  • Geminin labeling indices (LIs) in hyperplastic polyps, low-grade adenomas, high-grade adenomas, and intestinal-type adenocarcinomas were 3.9%, 10.5%, 18.6%, and 27.2%, respectively.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenoma / mortality. Adenoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Female. Fluorescent Antibody Technique. Geminin. Humans. Hyperplasia. Immunohistochemistry. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Multivariate Analysis. Polyps / mortality. Polyps / pathology. Prognosis. Regression Analysis. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20820987.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


23. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • However, basal ACS5 enzymatic activity was increased as a percentage of the total activity of ACSs in both groups, arguing for an absolute (group 1) or relative (group 2) increase in ACS5 enzymatic activity in all adenocarcinomas investigated.
  • These findings are reflected by in vitro analysis of three established colorectal adenocarcinoma cell lines, in which activity of ACS5 occurred.
  • [MeSH-major] Adenocarcinoma / metabolism. Coenzyme A Ligases / metabolism. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


24. Klopfleisch R, Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci; 2009 Aug;87(1):91-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.
  • To analyze their role in the malignant progression of canine mammary tumors expression levels of p27 and p21 and its major regulator p53 were compared in simple adenomas, adenocarcinomas of the mammary gland and lymph node metastases with normal mammary gland.
  • Laser microdissection of tissue samples and real-time PCR were used for quantification of mRNA expression levels. p21 was overexpressed in adenocarcinomas, whereas adenomas and metastases expressed p21 more heterogeneously.
  • Comparison of p21 expression in adenocarcinomas and their metastases revealed a significant decrease in expression in metastases.
  • In contrast, p27 expression was reduced in the adenocarcinomas but heterogeneously expressed in adenomas and metastases.
  • [MeSH-major] Adenocarcinoma / veterinary. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Dog Diseases / metabolism. Genes, p53 / physiology. Mammary Neoplasms, Animal / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185891.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


25. Iurin AG, Koval'skiĭ GB: [Proliferative activity by expression of antigen Ki-67 in solitary and multiple synchronous epithelial tumors of the colon]. Arkh Patol; 2005 Sep-Oct;67(5):38-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proliferative activity of sigmoid and rectal mucosa, and that of single and multiple (synchronous) adenomas and adenocarcinomas of the colon has been studied.
  • A significant difference between antigen Ki-67 expression index in normal mucosa, adenomas and adenocarcinomas, and also in single and multiple colorectal cancers has been revealed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Ki-67 Antigen / analysis. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323481.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


26. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


27. Klopfleisch R, Schütze M, Linzmann H, Brunnberg L, Gruber AD: Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas. J Comp Pathol; 2010 Jan;142(1):79-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas.
  • There is greater expression of Derl-1 mRNA in laser microdissected lymph node metastases of mammary adenocarcinomas than in non-neoplastic mammary gland tissue from the same dog.
  • Samples of primary mammary adenocarcinomas were collected from 54 dogs in addition to the nodal metastases of these tumours and intralymphatic neoplastic cells.
  • Samples of mammary adenomas were collected from a further 44 dogs in addition to non-neoplastic mammary gland from the same animals.
  • Weak Derl-1 expression was found in non-neoplastic gland and mammary adenomas, moderate expression in adenocarcinomas, moderate to marked expression in lymph node metastases and marked expression in intralymphatic tumour cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Dog Diseases / metabolism. Mammary Neoplasms, Animal / metabolism. Membrane Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632687.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins
  •  go-up   go-down


28. Klopfleisch R, Gruber AD: Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas. Vet Pathol; 2009 May;46(3):416-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas.
  • In this explorative study, BRCA1, BRCA2, and RAD51 mRNA expression was quantified in highly defined laser microdissected tissue samples of simple adenomas, adenocarcinomas of the mammary gland, and their lymph node metastases by real-time quantitative reverse transcription polymerase chain reaction.
  • In adenomas, mRNA expression was reduced for BRCA1 (6/10 dogs, 60%), BRCA2 (4/10 dogs, 40%), and RAD51 (4/10, 40%).
  • In adenocarcinomas BRCA1 expression varied with increased expression in 3 of 10 (30%) dogs and no differences in 7 of 10 (70%) dogs when compared with normal mammary gland.
  • BRCA2 and RAD51 were overexpressed in 5 of 10 (50%) and 6 of 10 (60%) of adenocarcinomas, respectively.
  • Further experimental studies are needed to clarify whether these changes in gene expression are a direct carcinogenetic stimulus or a protective response due to genetic instability during tumor progression.
  • [MeSH-major] Adenocarcinoma / metabolism. BRCA2 Protein / metabolism. Gene Expression Regulation, Neoplastic / physiology. Lymph Nodes / pathology. Mammary Neoplasms, Animal / metabolism. Rad51 Recombinase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176491.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; EC 2.7.7.- / Rad51 Recombinase
  •  go-up   go-down


29. Sandmeier D, Benhattar J, Martin P, Bouzourene H: Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology; 2009 Aug;55(2):206-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps.
  • AIMS: To compare the molecular profile of a series of sessile serrated adenomas (SSAs) and hyperplastic polyps (HPs), in order to distinguish these lesions, SSAs having a potential role in the genesis of serrated adenocarcinomas through a serrated pathway in which methylation plays a key role.
  • However, at least right-sided SSAs differ from left-sided SSAs and HPs in the occurrence of MLH1 and p16 methylation, supporting the hypothesis that SSAs could be precursors of serrated adenocarcinomas.
  • [MeSH-major] Adenoma / genetics. Colonic Polyps / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694828.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / beta Catenin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


30. Mishra PK, Jatawa SK, Raghuram GV, Pathak N, Jain A, Tiwari A, Varshney S, Maudar KK: Correlation of aberrant expression of p53, Rad50, and cyclin-E proteins with microsatellite instability in gallbladder adenocarcinomas. Genet Mol Res; 2009;8(4):1202-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of aberrant expression of p53, Rad50, and cyclin-E proteins with microsatellite instability in gallbladder adenocarcinomas.
  • Among the 40 samples, 23, 11, and 10 showed p53, Rad50, and cyclin-E expression, respectively, in moderately differentiated adenocarcinomas, demonstrating the prevalence and invasiveness of this disease in the methyl isocyanate-exposed population (P = 0.0009).
  • Nevertheless, co-expression of Rad50, and cyclin-E with p53 was absent in adenomas with dysplasia, demonstrating their independent roles.
  • Hence, these proteins may be useful as markers to identify premalignant lesions that are likely to progress into malignant adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin E / metabolism. DNA Repair Enzymes / metabolism. DNA-Binding Proteins / metabolism. Gallbladder Neoplasms / metabolism. Microsatellite Repeats / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19866438.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / Rad50 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


31. Arévalo F, Arias Stella C, Monge E: [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder]. Rev Esp Enferm Dig; 2007 Dec;99(12):694-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder].
  • [Transliterated title] Inmunoexpresión de p53 y ciclina D1 en adenomas de vesícula biliar.
  • INTRODUCTION: Gallbladder adenomas are infrequent neoplasms whose relation to adenocarcinoma is not well understood.
  • It has been suggested that adenomas and adenocarcinomas follow different molecular pathways.
  • MATERIAL AND METHODS: This is a comparative, cross-sectional study in which we compared p53 and D1 cyclin expression in adenomas and adenocarcinomas of the gallbladder.
  • Expression of p53 occurred in 83.3% of adenocarcinomas and in 16.6% of adenomas (p = 0.003).
  • D1 cyclin was expressed in a similar number of adenomas and adenocarcinomas.
  • CONCLUSION: Our results support the hypothesis that p53 is an important step in the pathogenesis of adenocarcinomas but not of adenomas of the gallbladder.
  • [MeSH-major] Adenoma / metabolism. Cyclin D1 / biosynthesis. Gallbladder Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290692.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


32. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


33. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chicken-skin mucosa (CSM) is an endoscopic finding initially described associated with adenomatous polyps and adenocarcinoma, suggesting a preneoplastic lesion.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Hashimoto Y, Skacel M, Adams JC: Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer; 2008;8:185
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.
  • Loss of epithelial syndecan-1 has been reported in human colorectal adenocarcinomas, but whether this has prognostic significance remains undecided.
  • Here we have examined syndecan-1 expression and its potential prognostic value with reference to a clinically annotated tissue microarray for human colon adenocarcinomas.
  • METHODS: Syndecan-1 expression was examined by immunohistochemistry of a tissue microarray containing cores from 158 colorectal adenocarcinomas and 15 adenomas linked to a Cleveland Clinic, IRB-approved database with a mean clinical follow-up of 38 months.
  • On adenocarcinoma cells, syndecan-1 was present around cell membranes and in cytoplasm.
  • In 87% of adenocarcinomas, syndecan-1 was decreased or absent; only 13% of patients had stained for syndecan-1 on more than 75% of tumor cells.
  • CONCLUSION: Syndecan-1 immunoreactivity was decreased in the majority of human colon adenocarcinomas in correlation with TNM stage and metastasis to local lymph nodes.
  • In a small fraction of adenocarcinomas, syndecan-1 was upregulated in the local stroma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Syndecan-1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Genomics. 2006;7:83 [16620374.001]
  • [Cites] Oral Oncol. 2006 May;42(5):493-500 [16364677.001]
  • [Cites] Respir Res. 2006;7:95 [16813649.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(3):505-28 [17097330.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1407-16 [16953225.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1118-26 [17375048.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6844-53 [17638895.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2851-63 [17666434.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):149-59 [18027090.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):12-20 [10962434.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):1-6 [11241302.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4905-7 [11326638.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1074-81 [11676858.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4517-31 [12414997.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9243-53 [14681683.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1373-82 [15177497.001]
  • [Cites] Oncology. 2004;67(1):11-8 [15459490.001]
  • [Cites] Cell Regul. 1991 Jan;2(1):1-11 [2007184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):932-6 [1736308.001]
  • [Cites] Annu Rev Cell Biol. 1992;8:365-93 [1335744.001]
  • [Cites] J Biol Chem. 1994 Aug 5;269(31):20013-9 [8051085.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):319-23 [8054282.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):423-31 [8695359.001]
  • [Cites] J Cell Sci. 1996 Jun;109 ( Pt 6):1393-403 [8799827.001]
  • [Cites] Virchows Arch. 1999 Feb;434(2):121-5 [10071246.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23(4):641-50 [15743035.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):776-83 [15810155.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5758-65 [15843578.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1109-15 [15851381.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3678-91 [15930135.001]
  • [Cites] Oncology. 2005;68(4-6):306-13 [16020957.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):621-7 [16739330.001]
  • (PMID = 18590537.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2459187
  •  go-up   go-down


35. García-Solano J, Pérez-Guillermo M, Conesa-Zamora P, Acosta-Ortega J, Trujillo-Santos J, Cerezuela-Fuentes P, Mäkinen MJ: Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol; 2010 Oct;41(10):1359-68
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma.
  • Colorectal serrated adenocarcinoma represents a subtype of colorectal carcinoma that originates from serrated adenomas.
  • The aim of this work was to test the diagnostic reproducibility of previously proposed histologic criteria for serrated adenocarcinoma and to analyze the clinicopathologic features and outcome that would warrant its recognition as a new subtype of colorectal cancer.
  • Nine hundred twenty-seven consecutive colorectal cancer specimens were used to search for cases fulfilling the criteria of serrated adenocarcinoma and matched controls.
  • Clinicopathologic findings of 85 serrated adenocarcinomas were compared with a matched control group of conventional cancers.
  • Serrated adenocarcinomas were encountered in 9.1% (n = 85) of cases.
  • Residual serrated adenoma was present in 44 (51.7%).
  • Absence of residual adenoma did not have any influence on the parameters studied.
  • Compared with their matched controls, serrated adenocarcinomas were more often accompanied by synchronous residual serrated adenomas (P < .0001), remote serrated adenomas (P = .0035), and serrated adenocarcinomas or cancers representing partial features of these tumors (P = .002).
  • Serrated adenocarcinoma is an identifiable subset of colorectal cancer; and the histopathologic differences, in addition to its less favorable prognosis, may justify its recognition as a distinct subset of colorectal cancer warranting the search for specific clinical management strategies.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 20594582.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. St Hill CA, Farooqui M, Mitcheltree G, Gulbahce HE, Jessurun J, Cao Q, Walcheck B: The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer; 2009 Mar 06;9:79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas.
  • Our goal was to determine the expression profiles of C2-O-sLex in the malignant progression and metastasis of colorectal adenocarcinomas.
  • Using CHO-131 mAb, we investigated whether C2-O-sLex was present in 113 human primary colorectal adenocarcinomas, 10 colorectal adenomas, 46 metastatic liver tumors, 28 normal colorectal tissues, and 5 normal liver tissues by immunohistochemistry.
  • We also examined mRNA levels of the enzyme core 2 beta1,6-N-acetylglucosaminyltransferase (C2GnT1) in 20 well, 15 moderately, and 2 poorly differentiated colorectal adenocarcinomas, and in 5 normal colorectal tissues by using quantitative real-time polymerase chain reactions (RT-PCR).
  • RESULTS: We observed high reactivity with CHO-131 mAb in approximately 70% of colorectal carcinomas and 87% of metastatic liver tumors but a lack of reactivity in colorectal adenomas and normal colonic and liver tissues.
  • Positive reactivity with CHO-131 mAb was very prominent in neoplastic colorectal glands of well to moderately differentiated adenocarcinomas.
  • The most intense staining with CHO-131 mAb was observed at the advancing edge of tumors with the deepest invasive components.Finally, we analyzed C2GnT1 mRNA levels in 37 colorectal adenocarcinomas and 5 normal colorectal tissues by RT-PCR.
  • Significantly, we observed a greater than 15-fold increase in C2GnT1 mRNA levels in colorectal adenocarcinomas compared to normal colorectal tissues.
  • CONCLUSION: C2-O-sLex, detected by the CHO-131 mAb, is a tumor associated antigen whose expression is highly upregulated in colorectal adenocarcinomas and metastatic liver tumors compared to normal tissues.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosci Lett. 2003 Mar 13;339(1):62-6 [12618301.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26391-400 [12736247.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1673-7 [1689848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13771-6 [10570148.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):11-24 [10636097.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1132-5 [1701275.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):324-30 [1371572.001]
  • [Cites] J Cell Biol. 1992 May;117(4):895-902 [1374413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9326-330 [1329093.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):657-66 [7679706.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2978-86 [7684623.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3632-7 [8101764.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2323-30 [8104679.001]
  • [Cites] Semin Cancer Biol. 1993 Oct;4(5):319-24 [7903054.001]
  • [Cites] Immunology. 1994 Feb;81(2):303-8 [7512530.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):901-7 [7515860.001]
  • [Cites] Exp Cell Res. 1995 Jan;216(1):215-21 [7529188.001]
  • [Cites] Cell Biophys. 1993 Aug-Dec;23(1-3):3-89 [7895250.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37987-97 [12847092.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):21984-91 [15026421.001]
  • [Cites] Int Surg. 2004 Apr-Jun;89(2):100-6 [15285243.001]
  • [Cites] Blood. 1983 Nov;62(5):1022-6 [6194834.001]
  • [Cites] Biochim Biophys Acta. 1985;780(2):119-50 [3890942.001]
  • [Cites] Cancer. 1986 May 1;57(9):1866-70 [3485470.001]
  • [Cites] Biol Chem Hoppe Seyler. 1988 Aug;369(8):661-5 [2905604.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6883-8 [2573422.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):455-60 [7538975.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] J Invest Dermatol. 1996 Apr;106(4):611-5 [8617993.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1996 Feb;97(2):140-4 [8632742.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3255-64 [8621728.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):290-4 [8797870.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Glycoconj J. 1996 Dec;13(6):1043-7 [8981096.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):816-25 [9053509.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):420-31 [9106690.001]
  • [Cites] Cancer. 1997 May 1;79(9):1686-97 [9128983.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):612-9 [9178816.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):296-300 [9221808.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5201-6 [9393734.001]
  • [Cites] Glycoconj J. 1998 Feb;15(2):177-82 [9557878.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Immunity. 1998 Dec;9(6):881-90 [9881978.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4504-12 [9988682.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):461-72 [10433939.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24838-48 [10455156.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):105-13 [15596301.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3267-76 [16418723.001]
  • [Cites] J Invest Dermatol. 2006 Sep;126(9):2065-73 [16691194.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4742-8 [16982914.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):347-53 [10639580.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7839-53 [10713099.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11106-13 [10753916.001]
  • [Cites] APMIS. 2000 Oct;108(10):705-12 [11200826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7 [11248082.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2226-31 [11280791.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11007-15 [11118434.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3812-9 [11389021.001]
  • [Cites] APMIS. 2001 Jul-Aug;109(7-8):500-6 [11552947.001]
  • [Cites] Expert Opin Biol Ther. 2001 Mar;1(2):253-75 [11727534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8 [11854515.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4063-9 [12010808.001]
  • (PMID = 19267921.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5KO8CA111829-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / E-Selectin; 0 / Polysaccharides; 0 / RNA, Messenger; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.102 / beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase
  • [Other-IDs] NLM/ PMC2662873
  •  go-up   go-down


37. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT: The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology; 2010 Mar-Apr;57(98):251-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This study is aimed to investigate abnormal expression of the Rb protein (pRb), p16(INK4a) (p16) and cyclin D1 in colorectal adenomas and adenocarcinomas and to assess the possible alterations in Rb pathway in colorectal carcinogenesis.
  • METHODOLOGY: 44 cases of colorectal adenoma and 44 cases of colorectal adenocarcinoma were examined histopathologically and immunohistochemically using monoclonal antibodies to identify abnormalities of pRb, p16, and cyclin D1 expression.
  • RESULTS: In 70.5% of the adenomas and 97.7% of the adenocarcinomas, an overexpression of pRb was found.
  • There was a statistically significant relationship between the immunoreactivity of pRb and villous/tubulovillous types of adenomas (p < 0.05).
  • There was a loss of p16 expression in 84.1% of adenomas and 61.4% of adenocarcinomas.
  • Statistically significantly, the p16 overexpression was not seen in any of tubular adenomas (p < 0.001).
  • Overexpression of cyclin D1 was found in only 9.1% of adenomas, while 31.8% of adenocarcinomas overexpressed this protein.
  • Loss of expression of cyclin D1 was similar in adenomas and adenocarcinomas (27.3% and 25%, respectively).
  • Staining degrees of all three cell cycle proteins were shown to be statistically different in adenomas and adenocarcinomas, for pRb (p = 0.001), for p16 ( p = 0.045), and cyclin D1 ( p = 0.05).
  • Also, there was only a mild agreement with respect to p16 and cyclin D1 relationship between for adenomas ( K = +0.28 p = 0.051) and for adenocarcinomas ( K = +0.35 p = 0.017).
  • CONCLUSIONS: pRb, p16 and cyclin D1 are shown to be aberrantly expressed in both colorectal adenomas and adenocarcinomas.
  • It can be claimed that disturbances in Rb pathway take part in colonic carcinogenesis and pRb, p16 and cyclin D1 play an ever increasing role in the further stages of adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Retinoblastoma Protein / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583423.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1
  •  go-up   go-down


38. Schneider AR, Seifert H, Trojan J, Stein J, Hoepffner NM: Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study. Z Gastroenterol; 2005 Oct;43(10):1123-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study.
  • METHODS: 26 consecutive patients (16 women, 10 men; median age 59 years) with sporadic adenomas (n = 19) or adenocarcinomas (n = 7) of the ampulla of Vater were retrospectively evaluated.
  • [MeSH-major] Adenocarcinoma / complications. Adenoma / complications. Ampulla of Vater. Common Bile Duct Neoplasms / complications. Intestinal Polyps / epidemiology
  • [MeSH-minor] Adenoma, Villous / complications. Adenoma, Villous / surgery. Adenomatous Polyposis Coli / epidemiology. Adult. Aged. Aged, 80 and over. Colonic Polyps / diagnosis. Colonic Polyps / epidemiology. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220451.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL: Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res; 2007 Mar 10;313(5):1033-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells.
  • In an analysis of human colon normal mucosa and tumors at different stages by immunohistochemistry, we observed that the intensity of BMP-4 staining in late-adenocarcinomas was stronger than that in normal mucosa and adenomas, while there was no difference in the staining of its receptors (BMPR-IA and BMPR-II) at all stages.
  • [MeSH-major] Adenocarcinoma / metabolism. Bone Morphogenetic Proteins / metabolism. Cell Movement. Colonic Neoplasms / metabolism. Intestinal Mucosa / metabolism. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275810.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type I; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


40. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


41. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients].
  • To estimate diagnostic value of K-ras mutations during cancer risk group formation, they were studied in the samples of sporadic carcinomas (n = 33) and malignant (n = 13) polyps of large intestine obtained during surgery or polypectomy.
  • The maximum mutation frequency was revealed in polyps of patients over 70 years of age as well as in the adenomas of villous histology and large size ((1 cm).
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


42. Gostjeva EV, Zukerberg L, Chung D, Thilly WG: Bell-shaped nuclei dividing by symmetrical and asymmetrical nuclear fission have qualities of stem cells in human colonic embryogenesis and carcinogenesis. Cancer Genet Cytogenet; 2006 Jan 1;164(1):16-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large cell nuclei with at least eight distinct morphologies have been discovered throughout the fetal gut (5-7 weeks), colonic adenomas, and adenocarcinomas, five of which are not present in the normal adult colon.
  • Cells containing these differentiated nuclear forms subsequently divide extra-syncytially by mitoses that form clonal populations of cells with identical nuclear morphotypes in embryos, adenomas, adenocarcinomas, and metastases.
  • Cells with bell-shaped nuclei thus appear to be responsible for both net growth and differentiation in the embryonic gut, adenomas, and adenocarcinomas, and fulfill the requirements for post-embryonic stem cells in colon organogenesis and carcinogenesis.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364758.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Ohara T, Morishita T, Suzuki H, Hibi T: Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med; 2006 Jul;18(1):59-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas.
  • Of these, 22 had well-differentiated and 20 had poorly-differentiated adenocarcinomas, the latter group including 10 with signet ring cell carcinomas.
  • The remaining 6 had gastric adenomas.
  • None of the healthy volunteers, patients with gastric adenomas or those with well-differentiated gastric adenocarcinomas showed mutations.
  • However, 8 of the 20 with poorly-differentiated gastric adenocarcinoma showed heterozygosity at the 135th position of the amino acid sequence of TLR4, and a mutation from threonine to alanine was found at this site.
  • This suggests a disturbance in the protein phosphorylation reaction of TLR4, and that this disturbance is related to the development of poorly-differentiated gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Polymorphism, Genetic / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786156.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 6; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors
  •  go-up   go-down


44. Nowak M, Madej JA, Dziegiel P: Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas. In Vivo; 2009 Sep-Oct;23(5):705-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas.
  • Localization and intensity of BCRP-1 expression was evaluated in mammary adenocarcinomas and adenomas in dogs.
  • MATERIALS AND METHODS: Materials for the study were sampled in the course of surgery from 54 dogs, of various breeds, aged 6 to 16 years (36 cases of mammary adenocarcinoma and 18 cases of mammary adenoma).
  • RESULTS: Expression of BCRP-1 was detected in over 85% of adenocarcinomas and almost 28% of adenomas.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / veterinary. Adenoma / veterinary. Mammary Neoplasms, Animal / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779104.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Kuno T, Kamataki T, Imaida K: 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Rep; 2009 Jul-Aug;2(4):585-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
  • Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.
  • In the present study, we examined the inhibitory effects of methoxsalen on the development of lung adenocarcinomas, as well as on adenomas and alveolar hyperplasia.
  • The experiments were terminated 52 weeks after the first methoxsalen treatment, and lung adenomas and adenocarcinomas were analyzed histopathologically.
  • Pretreatment with methoxsalen significantly reduced the incidence of adenocarcinomas from 94.7 to 46.7% (12.5 mg/kg) and 44.4% (1.25 mg/kg), and their tumor multiplicity from 4.68 to 0.87 (12.5 mg/kg) and 0.61 (1.25 mg/kg) tumors/mouse.
  • The tumor multiplicity of adenomas and adenocarcinomas in the methoxsalen-treated groups was significantly reduced from 12.47 to 5.67 (12.5 mg/kg) and 4.28 (1.25 mg/kg) tumors/mouse.
  • Approximately 60% of the adenocarcinomas arose within adenomas.
  • In comparing the methoxsalen + NNK and NNK alone groups, there was no significant difference in the frequency of such compound lesions, indicating that pretreatment with methoxsalen did not suppress the eventual progression of adenomas to adenocarcinomas.
  • These results clearly demonstrate that methoxsalen, a potent human CYP2A6 inhibitor, inhibits not only lung adenoma but also adenocarcinoma development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475870.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


46. Kuno T, Yokohira M, Matsuda Y, Suzuki S, Hashimoto N, Yamakawa K, Saoo K, Imaida K: Lack of modifying potential of 8-methoxypsoralen in the promotion or progression stages of lung carcinogenesis in A/J female mice. Oncol Rep; 2008 Oct;20(4):767-72
Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since it has been reported that CYP2A protein is highly expressed in NNK-induced lung adenomas and adenocarcinomas, potential anticancer properties of 8-MOP in female A/J mice were examined subsequent to initiation.
  • On immunohistochemical analysis, the CYP2A protein was found to be overexpressed in all lung adenomas and adenocarcinomas, with or without 8-MOP.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813816.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CYP2A6 protein, human; 0 / Enzyme Inhibitors; 0 / Nitrosamines; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; EC 1.14.13.- / Cytochrome P-450 CYP2A6; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp2a5 protein, mouse; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


47. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA: The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology; 2009 May;136(5):1669-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, increased HuR expression and cytoplasmic localization were observed in 76% of adenomas and 94% of adenocarcinomas, and TTP expression was lost in >75% of adenomas and adenocarcinomas.
  • In both adenomas and adenocarcinomas, COX-2 overexpression was associated with increased HuR and decreased TTP (P < .0001); similar associations were observed in colon cancer cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Cell Line, Tumor. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. HeLa Cells. Humans. Immunohistochemistry. RNA, Messenger / analysis. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2157-61 [15781626.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Cancer. 2006;5:37 [16982006.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] J Cell Biochem. 2007 Apr 15;100(6):1477-92 [17133347.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 15;462(2):278-85 [17517366.001]
  • [Cites] Expert Opin Biol Ther. 2007 Oct;7(10):1515-29 [17916044.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1124-36 [18644977.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2030-42, 2042.e1-3 [18824170.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):777-89 [16168373.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):125-31 [10721704.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17827-37 [10751406.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33951-6 [10930401.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1469-74 [11506952.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1657-65 [11733561.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1037-41 [12003384.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):394-9 [12671683.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:52-71 [12795048.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7146-54 [14562043.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7591-4 [14633672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2011-6 [14769925.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32393-400 [15187092.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3448-60 [9628880.001]
  • [CommentIn] Gastroenterology. 2009 May;136(5):1495-8 [19327732.001]
  • (PMID = 19208339.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCI NIH HHS / CA / R01 CA134609
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS488861; NLM/ PMC3742387
  •  go-up   go-down


48. Woo VL, Bhuiya T, Kelsch R: Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct;102(4):495-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas.
  • OBJECTIVE: Distinguishing between adenoid cystic carcinoma (ACC), polymorphous low-grade adenocarcinoma (PLGA), and monomorphic adenoma (MA) can occasionally pose a diagnostic challenge.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997117.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Vainer B, Horn T, Nielsen OH: Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms. Scand J Gastroenterol; 2006 Mar;41(3):318-25
Genetic Alliance. consumer health - Inflammatory bowel disease 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to assess the ICAM-1 expression in human colonic tissue representing UC, Crohn's disease (CD), adenomas, and adenocarcinomas, with special attention to the epithelium.
  • Colonic tissue from 10 patients with UC, 10 with CD, 32 adenomas, 27 adenocarcinomas, and 10 lymph node metastases were included.
  • Similar observations were made in the case of adenomas and adenocarcinomas, but in adenocarcinomas the epithelial ICAM-1 was more diffuse and not related solely to sites of surface destruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497620.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


50. Shanmugam C, Katkoori VR, Jhala NC, Grizzle WE, Siegal GP, Manne U: p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior. J Histochem Cytochem; 2008 Mar;56(3):305-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior.
  • For subsets of colorectal adenocarcinoma (CRC) patients, nuclear accumulation of p53 (p53(nac)) and Bcl-2 expression are prognostic indicators.
  • These findings suggest that in those adenomas that demonstrate p53(nac) but lack Bcl-2 expression, their contiguous CRCs are more likely to be aggressive as they progress.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Cancer Biomark. 2005;1(4-5):241-50 [17192048.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3907-12 [11268475.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):959-70 [12489272.001]
  • [Cites] Cell. 2004 Feb 20;116(4):527-40 [14980220.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Pathol. 1989 Mar;157(3):193-9 [2926561.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):807-13 [1707233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 [1584781.001]
  • [Cites] Cell Growth Differ. 1993 Jan;4(1):41-7 [8424905.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1791-8 [8183578.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1799-805 [8183579.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3367-70 [7936663.001]
  • [Cites] N Engl J Med. 1995 Jun 1;332(22):1521-2 [7739705.001]
  • [Cites] Hum Pathol. 1995 May;26(5):534-40 [7750937.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):981-5 [7547253.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1176-81 [7587760.001]
  • [Cites] J Pathol. 1996 Mar;178(3):264-7 [8778330.001]
  • [Cites] J Pathol. 1996 Apr;178(4):393-7 [8691316.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jul;120(7):654-9 [8757470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6979-90 [9003774.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1864-9 [9667660.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):523-7 [9870685.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2456-67 [9874449.001]
  • [Cites] Pathol Int. 1999 May;49(5):374-82 [10417679.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5451-61 [16061861.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):159 [16971940.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):423-30 [11008204.001]
  • (PMID = 18071066.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / R01-CA-98932-01; United States / NCI NIH HHS / CA / U24-CA-086359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2324183
  •  go-up   go-down


51. Goere D, Elias D: [Appendiceal tumors found at appendectomy]. J Chir (Paris); 2009 Oct;146 Spec No 1:36-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are three main histologic types of appendiceal tumor: adenoma, adenocarcinoma, and neuroendocrine tumor.
  • Adenomas and adenocarcinomas are both rare; they share two particularities: (a) a mucinous component is both frequent and predominant, (b) they have a tendency to intraperitoneal dissemination.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenoma / diagnosis. Adenoma / surgery. Humans. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / surgery. Peritoneal Neoplasms / prevention & control. Pseudomyxoma Peritonei / prevention & control. Rupture / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846099.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 7
  •  go-up   go-down


52. Sawasaki T, Katsube Y: The Ep-CAM: A potential candidate for diagnosis in ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ep-CAM expression was examined by semiquantitative PCR in 122 ovarian tumors (92 adenocarcinomas, 10 low malignant potential (LMP) tumors, and 10 adenomas) and 10 normal ovaries.
  • RESULTS: In carcinomas as well as LMP tumors and adenomas, Ep-CAM mRNA expression was significantly elevated compared to that in normal ovary samples.
  • Ep-CAM mRNA expression level in carcinomas was significantly elevated compared to that in adenomas and Ep-CAM mRNA expression level in advanced clinical stage diseases was significantly higher than that in early stage diseases in ovarian carcinomas.
  • With regard to histological type, Ep-CAM mRNA expression level in mucinous adenocarcinomas was significantly higher than those in the other tissue subtypes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961514.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Han HS, Lee SY, Seong MK, Kim JH, Sung IK, Park HS, Jin CJ, Hwang TS: Presence of iron in colorectal adenomas and adenocarcinomas. Gut Liver; 2008 Jun;2(1):19-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of iron in colorectal adenomas and adenocarcinomas.
  • In this study, we attempted to determine the significance of tissue iron in colorectal adenomas and adenocarcinomas.
  • METHODS: This study investigated 138 colorectal neoplasms (54 adenocarcinomas, 25 adenomas with high-grade dysplasia, and 59 adenomas with low-grade dysplasia) that were removed by surgical or endoscopic resection in Konkuk University Hospital between August 2005 and August 2006.
  • RESULTS: Positive Perls' staining was evident in 35.2% (19/54) of the adenocarcinomas and 22.6% (19/84) of the adenomas, and in only 2.2% (3/138) of the samples of adjacent normal colon tissue (p<0.001).
  • Iron expression was strong in larger (p=0.004) and pedunculated (p<0.001) adenomas, and in all types of adenocarcinomas regardless of their size, shape, and location.
  • CONCLUSIONS: The frequent presence of iron in the stroma of large adenomas, pedunculated adenomas, and adenocarcinomas indicates that iron deposition is a secondary phenomenon to intralesional hemorrhage rather than a consequence of epithelial-cell carcinogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2006 Oct;55(10):1384-6 [16966697.001]
  • [Cites] Gut. 2006 Oct;55(10):1449-60 [16641131.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):1004-9 [16733117.001]
  • [Cites] Dig Dis Sci. 2005 Apr;50(4):696-707 [15844705.001]
  • [Cites] Biol Trace Elem Res. 2003 Oct;95(1):19-28 [14555796.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):503-7 [8827353.001]
  • [Cites] J Natl Cancer Inst. 1994 Mar 16;86(6):455-60 [8120921.001]
  • [Cites] Histol Histopathol. 1992 Oct;7(4):543-7 [1457975.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1333-6 [15362746.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s211-3 [15655626.001]
  • (PMID = 20485606.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871572
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenoma / Colorectal neoplasm / Iron
  •  go-up   go-down


54. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science; 2009 Mar 27;323(5922):1747-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the offspring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas.


55. Hochwartner O, Loupal G, Wildgoose WH, Schmidt-Posthaus H: Occurrence of spontaneous tumours of the renal proximal tubules in oscars Astronotus ocellatus. Dis Aquat Organ; 2010 Mar 9;89(2):185-9
Bern Open Repository and Information System. Free Full text from BORIS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes the occurrence of renal papillary cystic adenomas and adenocarcinomas in oscars Astronotus ocellatus Cuvier, 1829.
  • [MeSH-major] Adenoma / veterinary. Cichlids. Fish Diseases / pathology. Kidney Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402236.001).
  • [ISSN] 0177-5103
  • [Journal-full-title] Diseases of aquatic organisms
  • [ISO-abbreviation] Dis. Aquat. Org.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Lozynska M: The prognostic value of cytogenetic markers for early diagnosis of colorectal cancer. Exp Oncol; 2009 Dec;31(4):237-41
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of cytogenetic markers for early diagnosis of colorectal cancer.
  • AIM: To investigate the spectrum of chromosome changes in colorectal adenomas and adenocarcinomas and to evaluate the prognostic significance of the chromosome rearrangements.
  • METHODS: The study was carried out using the cytogenetic analysis of biopsy specimens (n = 56) of single and multiply adenomas (familial adenomatous syndromes; n = 38) and adenocarcinomas (n = 18).
  • RESULTS: The karyotype of adenomas was normal in the majority of cases, but some adenomas with severe dysplasia of epithelium carry the quantitative chromosome abnormalities and structural rearrangements.
  • The combination of additional copies of chromosomes 13, 18, 20 in adenomas points on an unfavorable prognosis.
  • The chromosome abnormalities were found in 100% of adenocarcinomas biopsy specimens.
  • CONCLUSIONS: The transition from colorectal adenomas to adenocarcinomas is accompanied by elevation of chromosome abnormalities level, in particular, by increased clonal variety, selective accumulation of the copies of chromosomes 2, 3, 20, 16, with simultaneous monosomy of chromosomes 17, 18, 8, 6, 14, and del 1p.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Biomarkers, Tumor / genetics. Chromosome Aberrations. Colorectal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010528.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


58. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


59. Kang WY, Chen WT, Wu MT, Chai CY: The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis; 2007 Aug;22(8):869-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma.
  • BACKGROUND: The aim of our study was to analyze the expression and possible role of CD66a in colorectal adenoma and adenocarcinoma and the relationship between its expression and pre-operation serum carcinoembryonic antigen (CEA) level and tumor stage in patients with colorectal adenocarcinomas.
  • METHODS: Paraffin-embedded sections from 184 patients including 42 colorectal adenomas with low-grade dysplasia, 43 adenomas with high-grade dysplasia, and 99 adenocarcinomas were collected for this study.
  • RESULTS: The expression of CD66a was found not only in the apical membrane of neoplastic glands but also in secretion within the lumen of the neoplastic glands including adenomas and adenocarcinomas.
  • Expressions of secreted CD66a were of higher level in adenocarcinoma than in adenoma with high-grade dysplasia and adenoma with low-grade dysplasia (p < 0.0001).
  • High expression of secreted CD66a was also associated with tumor stage, invasion, and pre-operation serum CEA level of patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenoma / immunology. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Colorectal Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143599.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CTNNB1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


60. Diehl D, Oesterle D, Elmlinger MW, Hoeflich A, Wolf E, Lahm H: IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment. J Carcinog; 2006;5:24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant crypt foci (ACF) served as markers of early lesions in the colonic mucosa, whereas adenomas and carcinomas characterized the endpoints of tumor development.
  • Nevertheless, adenomas and adenocarcinomas of the colon, present after 34 weeks in both genetic groups, were not found at different frequency.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21092-8 [12657632.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] Lancet. 1992 Sep 12;340(8820):626-30 [1355210.001]
  • [Cites] Cell Struct Funct. 2003 Aug;28(4):255-63 [14586135.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):862-6 [14624779.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2642-9 [14669304.001]
  • [Cites] Carcinogenesis. 2004 Apr;25(4):527-33 [14688025.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1600-3 [14996716.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Apr;288(4):F703-13 [15572521.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1236-40 [2917353.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6187-92 [3167865.001]
  • [Cites] Endocrinology. 1994 Nov;135(5):1877-86 [7525257.001]
  • [Cites] Exp Cell Res. 1995 Feb;216(2):342-51 [7531153.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] J Pathol. 1995 May;176(1):37-44 [7616355.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3141-53 [15735679.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1819-22 [16030122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15593-8 [16230630.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):561-71 [16375662.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):287-94 [1706308.001]
  • [Cites] Carcinogenesis. 1991 Nov;12(11):2093-8 [1934294.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):624-30 [1991846.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):452-9 [8050827.001]
  • [Cites] Mutagenesis. 1996 May;11(3):241-5 [8671746.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):781-90 [9797687.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1276-80 [9809551.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):509-13 [10190570.001]
  • [Cites] Gut. 1999 May;44(5):704-8 [10205209.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3278-88 [10207053.001]
  • [Cites] Immunol Cell Biol. 1999 Jun;77(3):256-62 [10361258.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):15-7 [10449601.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1070-6 [10706126.001]
  • [Cites] Cell Prolif. 2000 Feb;33(1):1-18 [10741640.001]
  • [Cites] Toxicol Lett. 2000 Jun 5;115(3):205-12 [10814890.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1117-20 [10836998.001]
  • [Cites] Growth Horm IGF Res. 1998 Jun;8(3):185-93 [10984306.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1344-50 [11044360.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):901-5 [12223436.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38239-44 [12154096.001]
  • [Cites] Growth Horm IGF Res. 2002 Feb;12(1):69-79 [12127304.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7318-24 [11585772.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):315-20 [11181454.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]
  • (PMID = 17118177.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660565
  •  go-up   go-down


61. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


62. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


63. Uchiyama Y, Imazu H, Kakutani H, Hino S, Sumiyama K, Kuramochi A, Tsukinaga S, Matsunaga K, Nakayoshi T, Goda K, Saito S, Kaise M, Kawamuara M, Omar S, Tajiri H: New approach to diagnosing ampullary tumors by magnifying endoscopy combined with a narrow-band imaging system. J Gastroenterol; 2006 May;41(5):483-90
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All adenomas and adenocarcinomas had type II and/or type III surface structures, and patients whose ampulla had a type I surface structure had only inflammatory or hyperplastic changes.
  • In addition, abnormal vessels were seen only in adenocarcinomas and never in adenomas.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Aged. Biopsy. Female. Follow-Up Studies. Humans. Inflammation. Male. Microscopy, Video. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799891.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia; 2008 Mar;10(3):287-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunohistochemical staining reveals that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive correlation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):257-70 [15713897.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):833-8 [16049285.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1184-91 [16489072.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1445-51 [16685378.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2668-70 [16963263.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] J Clin Pathol. 2007 Feb;60(2):173-9 [17264243.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1123-32 [17317820.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1577-85 [16953222.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2497-507 [17363567.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2517-25 [17363569.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12249-59 [17307743.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4940-8 [17510424.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3654-60 [17530019.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5389-96 [17545620.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5112-21 [17332240.001]
  • [Cites] Gut. 2007 Sep;56(9):1257-65 [17449633.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Science. 2000 Jan 7;287(5450):142-4 [10615050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5405-10 [10792035.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):10-24 [10862190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1543-8 [11171987.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17397-405 [11859072.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):548-54 [12555068.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):894-905 [12584569.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1638-52 [12642867.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1270-9 [12649187.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5399-407 [12934099.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6109-18 [15342394.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • (PMID = 18320073.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cysteine Proteinase Inhibitors; 0 / Leupeptins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / Tyrphostins; 0 / Vascular Endothelial Growth Factor A; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / PTK2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2259457
  •  go-up   go-down


65. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, Okanoue T, Hattori T: Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci; 2005 Sep;50(9):1741-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.
  • The entity of serrated adenoma of the colorectum was first proposed in 1990, and it was characterized as epithelial neoplasia combining the architectural features of a hyperplastic polyp with the cytological features of an adenoma.
  • Over the past few years, various clinicopathological studies on serrated adenoma have been reported, but its histogenesis remains unclear.
  • Recently the existence of a "serrated neoplasia pathway" leading to malignancy, which is different from the so-called adenoma-carcinoma sequence, has been discussed.
  • Yao et al. reported that hyperplastic polyps and serrated adenomas share a common cell lineage with gastric differentiation.
  • To clarify the existence of the serrated neoplasia pathway, we performed immunohistochemical staining of cytokeratin 7 (CK7) and cytokeratin 20 (CK20), which are commonly used to determine the primary site of a metastatic lesion, and we examined the pattern of CK7/CK20 expression in various colorectal lesions including 44 serrated adenomas, 25 hyperplastic polyps, 20 traditional adenomas, and 48 carcinomas.
  • An obvious difference existed in the pattern of CK7/CK20 expression between the serrated lesions (hyperplastic polyps and serrated adenomas) and others.
  • The majority of serrated adenomas and hyperplastic polyps presented a CK7+/CK20+ pattern, whereas most conventional adenomas and adenocarcinomas expressed CK7-/CK20+.
  • Adenocarcinoma developing in serrated adenoma also presented a CK7+/CK20+ pattern.
  • Taken together with the present results, a distinct pathway of colorectal carcinogenesis must exist, which is different from the adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Intermediate Filament Proteins / biosynthesis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


66. Matusiewicz M, Krzystek-Korpacka M, Diakowska D, Grabowski K, Augoff K, Blachut K, Paradowski L, Kustrzeba-Wojcicka I, Piast M, Banas T: Serum sulfatase activity is more elevated in colonic adenomas than cancers. Int J Colorectal Dis; 2008 Apr;23(4):383-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sulfatase activity is more elevated in colonic adenomas than cancers.
  • Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas.
  • The activity was more elevated in adenomas (149; 128-173 U) than in cancers (103; 90-112 U).
  • Sulfatase activity exceeded the cutoff value in 71% of AP and 47% of CRC patients.
  • It increased with number of adenomas and tended to decrease with tumor progression.
  • Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193432.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


67. Park SH, Kim SY, Lee SS, Bogoni L, Kim AY, Yang SK, Myung SJ, Byeon JS, Ye BD, Ha HK: Sensitivity of CT colonography for nonpolypoid colorectal lesions interpreted by human readers and with computer-aided detection. AJR Am J Roentgenol; 2009 Jul;193(1):70-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A computerized database search for a 33-month period found 21 patients who had undergone both colonoscopy and CTC and who had a total of 23 genuinely nonpolypoid colorectal lesions: eight adenomas (9-30 mm in width), 10 stage Tis or T1 adenocarcinomas (10-25 mm), and five nonadenomatous lesions (8-20 mm).
  • RESULTS: The sensitivities of human readers for nonpolypoid adenomatous lesions (i.e., both adenomas and adenocarcinomas), adenocarcinomas, and nonadenomatous lesions were 66.7% (12/18), 90% (9/10), and 0% (0/5), respectively.
  • A 10-mm stage T1 adenocarcinoma was missed by a human reader on blinded review but was detected with CAD.
  • Both human readers and CAD yielded significantly higher sensitivity for adenomatous lesions than for nonadenomatous lesions (p = 0.014 and 0.046, respectively) and for adenocarcinomas than for noncancerous lesions (p = 0.003 and 0.0001, respectively).
  • CONCLUSION: CTC showed a high sensitivity for nonpolypoid stage Tis and T1 adenocarcinomas 10 mm or greater in width despite the limited overall sensitivity for nonpolypoid adenomatous lesions, when performed using cathartic preparation and fecal tagging.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542397.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Woicke J, Durham SK, Mense MG: Lobucavir-induced proliferative changes in mice. Exp Toxicol Pathol; 2007 Nov;59(3-4):197-204
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Light microscopically, lobucavir-induced neoplastic lesions consisted of upper digestive tract squamous cell neoplasia in males and females; cervical, vaginal, and cutaneous squamous cell neoplasia in females; and Hardarian gland adenomas and adenocarcinomas in male mice.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942294.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Carcinogens; 5Z93L87A1R / Guanine; 8U5PYQ1R2E / lobucavir
  •  go-up   go-down


69. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol; 2007 Feb;170(2):693-708
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophils infiltrated the alveoli of tumor-bearing lungs and within the periphery of macroscopic adenomas and adenocarcinomas.
  • These biochemical markers of macrophage activation states would have diagnostic and/or therapeutic value if analogous systemic shifts occur in humans.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):1061-2 [11457936.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5023-32 [16585599.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1423-33 [11583970.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):509-18 [10666380.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6850-6 [12460898.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):186-98 [12539173.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Cell Mol Life Sci. 2003 Nov;60(11):2334-46 [14625680.001]
  • [Cites] Novartis Found Symp. 2004;256:137-45; discussion 146-8, 259-69 [15027487.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3458-64 [15150098.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1660-7 [15251154.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5084-8 [15289309.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] J Cell Sci. 1966 Sep;1(3):297-310 [4291022.001]
  • [Cites] Int J Cancer. 1967 Jul 15;2(4):326-36 [6055972.001]
  • [Cites] Cancer Res. 1969 May;29(5):994-8 [5781107.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] Immunology. 1984 Dec;53(4):753-67 [6389324.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):963-9 [3863993.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5335-8 [3756882.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):918-31 [2849325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3070-4 [2654935.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2709-14 [1401910.001]
  • [Cites] N Engl J Med. 1993 Jan 28;328(4):257-65 [8418407.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4848-50 [8069850.001]
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1415-25 [7931074.001]
  • [Cites] Genet Res. 1994 Oct;64(2):99-106 [7813906.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):385-8 [9247277.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7 [9814991.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2005-7 [16223785.001]
  • [Cites] J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204 [16335592.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):27-35 [10672781.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Eur Respir J. 2000 Jun;15(6):1087-93 [10885428.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2237-42 [11080091.001]
  • [Cites] Curr Opin Immunol. 2000 Dec;12(6):624-31 [11102764.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E75-82 [11120661.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • (PMID = 17255336.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033497; United States / NCI NIH HHS / CA / R01 CA096133; United States / NCI NIH HHS / CA / CA33497; United States / NCI NIH HHS / CA / CA96133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 3IN71E75Z5 / Urethane; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  • [Other-IDs] NLM/ PMC1851863
  •  go-up   go-down


70. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM: Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol; 2005 May;40(5):263-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The authors used K-ras mice, which develop lung adenomas and adenocarcinomas through somatic activation of the K-ras oncogene.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / pathology. Adenoma / radiography. Animals. Disease Models, Animal. Female. Male. Mice. Mice, Transgenic. Pilot Projects. Radiographic Image Enhancement. Reproducibility of Results. Respiration

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829823.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA80686; United States / NCI NIH HHS / CA / U01 CA84306
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


71. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H: The Intestinal Wnt/TCF Signature. Gastroenterology; 2007 Feb;132(2):628-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Independently, differential gene-expression profiles of human adenomas and adenocarcinomas vs normal colonic epithelium were obtained.
  • RESULTS: Expression analyses of approximately 80 genes common between these data sets were performed in a murine adenoma model.
  • CONCLUSIONS: The genes were invariably expressed in adenomas, yet could be subdivided into 3 modules, based on expression in distinct crypt compartments.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Animals. Cell Line, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression Profiling. Humans. Mice. Oligonucleotide Array Sequence Analysis. Paneth Cells / metabolism. RNA, Messenger / metabolism. T Cell Transcription Factor 1 / metabolism. Time Factors. Transcription Factor 7-Like 2 Protein. Transfection. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320548.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / T Cell Transcription Factor 1; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Tcf7l2 protein, mouse; 0 / Transcription Factor 7-Like 2 Protein; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


72. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • Our report is the first describing the possible malignant degeneration of a villous adenoma in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


73. Scherübl H: Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy; 2009 Feb;41(2):162-5
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, endoscopic screening of the colorectum is effective in the early diagnosis not only of colorectal adenomas and adenocarcinomas but also of carcinoids.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214898.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


74. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


75. Funovics MA, Alencar H, Montet X, Weissleder R, Mahmood U: Simultaneous fluorescence imaging of protease expression and vascularity during murine colonoscopy for colonic lesion characterization. Gastrointest Endosc; 2006 Oct;64(4):589-97
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two mouse models were used (Apcmin(+/-) mice for colonic adenomas and CT26 murine colon cancer).
  • Both colonic adenomas and adenocarcinomas were clearly visible in the NIR channel on protease probe administration in live mice.
  • Ratio imaging of protease activity/perfusion increased from healthy colon to adenomas to adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Adenoma / blood supply. Adenoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / blood supply. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Colonoscopes. Dermoscopy / instrumentation. Image Interpretation, Computer-Assisted / instrumentation. Neoplasms, Experimental / blood supply. Neoplasms, Experimental / pathology. Peptide Hydrolases / analysis. Spectroscopy, Near-Infrared / instrumentation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996355.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB001872; United States / PHS HHS / / P50 C 86355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.- / Peptide Hydrolases; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


76. Takizawa T, Imai T, Ueda M, Onodera H, Hirose M: Comparison of enhancing effects of different goitrogen treatments in combination with beta-estradiol-3-benzoate for establishing a rat two-stage thyroid carcinogenesis model to detect modifying effects of estrogenic compounds. Cancer Sci; 2006 Jan;97(1):25-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the long-term experiment after DHPN initiation, EB alone slightly increased small numbers of animals with follicular hyperplasias, adenomas and adenocarcinomas.
  • Simultaneous treatment with antithyroidal chemicals was associated with an increase in the incidences of focal hyperplasias, adenomas and/or adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005).
  • (PMID = 16367917.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Estrogens; 0 / Proliferating Cell Nuclear Antigen; 1S4CJB5ZGN / estradiol 3-benzoate; 4TI98Z838E / Estradiol
  •  go-up   go-down


77. Kondo E, Miyake T, Shibata M, Kimura T, Iwagaki H, Nakamura S, Tanaka T, Ohara N, Ichimura K, Oka T, Yanai H, Shibasaki F, Yoshino T: Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms. Clin Cancer Res; 2005 Oct 15;11(20):7255-63
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate this question that may suggest the biological role, we molecularly screened a panel of human colorectal adenomas and adenocarcinomas for endogenous expression of pSer70 Bcl-2.
  • EXPERIMENTAL DESIGN: An antibody specific against pSer70 Bcl-2 was generated for thorough immunohistochemical examination of paraffin-embedded tumor specimens, allowing detection of the endogenously expressed antigen among a range of Bcl-2-positive colorectal neoplasms, including 75 tubular adenomas, 114 adenocarcinomas, and 15 cases of cancer in adenomas.
  • RESULTS: Loss of pSer70 Bcl-2 expression was observed in adenocarcinomas in a differentiation-dependent manner (positivities: well differentiated 63%, moderately differentiated 52%, and poorly differentiated 12%), whereas tubular adenomas maintained their expression (positivity 88%).
  • Interestingly, an inverse correlation was found between expression of pSer70 Bcl-2 and Ki-67 antigen in those cases of cancer in adenoma (P < 0.01).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243795.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 452VLY9402 / Serine
  •  go-up   go-down


78. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


79. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H: Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. Cell Oncol; 2009;31(3):235-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: ERalpha, ERbeta and PELP1/MNAR protein expression were evaluated by immunohistochemistry in colorectal normal mucosa, adenomas and adenocarcinomas from 113 patients with colorectal cancer.
  • Additionally, the expression of both proteins was significantly increased in stromal myofibroblasts of carcinomas compared to adenomas and normal mucosa.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19478391.001).
  • [ISSN] 1875-8606
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Co-Repressor Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / PELP1 protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4618984
  •  go-up   go-down


80. Gui X, Guzman G, Dobner PR, Kadkol SS: Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides; 2008 Sep;29(9):1609-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma.
  • NT is expressed in fetal but not differentiated colonic epithelium and is re-expressed in colonic adenocarcinoma.
  • To further understand the possible role of NTSR1 expression in colonic tumorigenesis and progression, we examined NTSR1 mRNA by in situ hybridization in normal colonic mucosa, adenomas, and colonic adenocarcinomas.
  • NTSR1 mRNA expression was undetectable or weak in superficial differentiated epithelial cells of normal colonic epithelium, but adenomas and adenocarcinomas showed moderate to strong expression (p<0.05).
  • Adenocarcinomas showed a higher level of expression compared to adenomas (p<0.05).
  • Furthermore, adenocarcinomas that infiltrated into and beyond the muscularis propria showed a higher intensity of NTSR1 expression compared with tumors that were localized to the mucosa or submucosa.
  • These results suggest that increased NTSR1 expression may be an early event during colonic tumorigenesis and also contribute to tumor progression and aggressive behavior in colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Receptors, Neurotensin / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541341.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor
  •  go-up   go-down


81. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.
  • Among the 8 adenocarcinomas, 5 (62.5%) cases were classified as main duct type, and 3 (37.5%) as combined type.
  • In 7 of the 8 adenocarcinomas, mural nodules were detected within the dilated ducts or cysts of the lesions in which color flow signals were detected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem; 2010 Mar;58(3):277-85
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24A1) is considered to be the main enzyme determining the biological half-life of 1,25-D(3), we have examined expression of the CYP24A1 mRNA (by real-time RT-PCR) and protein (by immunohistochemistry) in normal human colon mucosa, colorectal adenomas, and adenocarcinomas in 111 patients.
  • Although 76% of the normal and benign colonic tissue was either completely devoid of or expressed very low levels of CYP24A1, in the majority of the adenocarcinomas (69%), the enzyme was present at high concentrations.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. Steroid Hydroxylases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2000 May;127(5):717-22 [10788778.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1581-9 [15905206.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6158-65 [11012668.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):847-52 [11075874.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):888-94 [11158062.001]
  • [Cites] Steroids. 2001 Mar-May;66(3-5):409-22 [11179750.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 27;285(4):1012-7 [11467853.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1583-8 [12352462.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):31-41 [16145679.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94 [16236494.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [16180015.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1424-33 [16247453.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):415-24 [16556015.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1819-28 [16708384.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1119-26 [17182978.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 [18089708.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Mol Aspects Med. 2008 Dec;29(6):388-96 [18755215.001]
  • [Cites] Recent Results Cancer Res. 2003;164:239-46 [12899526.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38084-93 [12867411.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):236-41 [14760115.001]
  • [Cites] J Cutan Pathol. 2004 Mar;31(3):224-31 [14984574.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):693-702 [15077124.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):985-9 [15208365.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Steroids. 1990 Sep;55(9):395-8 [2281516.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24673-8 [7929139.001]
  • [Cites] J Invest Dermatol. 1997 Apr;108(4):513-8 [9077483.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 May;62(1):21-8 [9366495.001]
  • [Cites] Endocrinology. 1999 May;140(5):2071-6 [10218956.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):82-90 [10337990.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20604-11 [15788398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7 [16103450.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):977-84 [10891358.001]
  • (PMID = 19901270.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2825493
  •  go-up   go-down


83. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P: Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res; 2006 Dec 1;66(23):11228-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This enzyme is generally not expressed by normal differentiated epithelial colon cells, but has been shown to be up-regulated in human colon adenomas and adenocarcinomas.
  • In this study, we show that LN5 and MMP7 are coexpressed in HT29 cells as well as in HT29 xenograft tumors and human colorectal adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Amino Acid Sequence. Animals. Animals, Newborn. Blotting, Western. Gene Expression Regulation, Neoplastic. HT29 Cells. Humans. Molecular Sequence Data. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145868.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / kalinin; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


84. Oyama T, Yasui Y, Sugie S, Koketsu M, Watanabe K, Tanaka T: Dietary tricin suppresses inflammation-related colon carcinogenesis in male Crj: CD-1 mice. Cancer Prev Res (Phila); 2009 Dec;2(12):1031-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of colonic adenomas and adenocarcinomas was significantly reduced by feeding with 50 and 250 ppm tricin, respectively.
  • Dietary tricin also significantly reduced the proliferation of adenocarcinoma cells as well as the numbers of mitoses/anaphase bridging in adenocarcinoma cells.
  • Our findings that dietary tricin inhibits inflammation-related mouse colon carcinogenesis by suppressing the expression of TNF-alpha in the nonlesional cyrpts and the proliferation of adenocarcinomas suggest a potential use of tricin for clinical trials of colorectal cancer chemoprevention.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenoma / prevention & control. Colonic Neoplasms / prevention & control. Diet. Flavonoids / administration & dosage. Inflammation / prevention & control. Phytotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934339.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Flavonoids; 0 / Plant Extracts; 0 / RNA, Messenger; D51JZL38TQ / tricin; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


85. Perse M, Zebic A, Cerar A: Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. Scand J Gastroenterol; 2005 Jan;40(1):61-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal tumours were evaluated quantitatively and histopathologically for the presence of aberrant crypt foci (ACF), adenomas and adenocarcinomas.
  • However, a significant lower incidence of adenomas (p < 0.05), adenocarcinomas (p < 0.05) and decreased volume of macroscopically visible tumours (by 42%) was found in the experimental group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841716.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


86. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer; 2008 Jan 29;8:33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
  • METHODS: By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.
  • RESULTS: Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28% = 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5 mixed polyps) (0% = 0/12, p = 0.04).
  • Furthermore, any (1+/2+) COX-2 overexpression was more frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p < 0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03).
  • Traditional serrated adenomas and non-serrated adenomas showed similar frequencies of COX-2 overexpression.
  • Regardless of serration, COX-2 overexpression was frequent (approximately 85%) in colorectal adenocarcinomas.
  • Tumor location was not significantly correlated with COX-2 overexpression, although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors (than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated adenomas and adenocarcinomas.
  • CONCLUSION: COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with SSA and adenoma, compared to non-serrated and serrated adenoma.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1998 Jul;28(7):421-6 [9739782.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4044-8 [10945606.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] Dig Dis Sci. 2004 Nov-Dec;49(11-12):1906-11 [15628724.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):130-8 [15654792.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):429-36 [15767794.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Oncology. 2005;69 Suppl 1:33-7 [16210875.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] BMC Cancer. 2006;6:9 [16409625.001]
  • [Cites] Histopathology. 2006 Mar;48(4):431-7 [16487365.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):458-64 [16820091.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] BMC Cancer. 2006;6:181 [16831226.001]
  • [Cites] J Pathol. 2006 Oct;210(2):137-40 [16917802.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1319-23 [11584208.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):144-9 [12049307.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):786-92 [12794581.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Aug;129(8):449-55 [12884030.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):267-71 [14734479.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):213-9 [14745394.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25 [15167166.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):27-39 [17078205.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2195-8 [17522404.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5473-7 [9850081.001]
  • (PMID = 18230181.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC2257954
  •  go-up   go-down


87. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, Dietel M, Denkert C: Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol; 2005 Sep 28;11(36):5644-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of PLK1 was investigated by immunohistochemistry (158 cases) and immunoblotting in tissue of colon adenomas and adenocarcinomas.
  • RESULTS: Weak PLK1 expression was observed in normal colon mucosa and adenomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237758.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC4481481
  •  go-up   go-down


88. Lisovsky M, Falkowski O, Bhuiya T: Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol; 2006 Dec;37(12):1601-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although identification of epithelial dysplasia in Barrett's esophagus (BE) is critically important because of a significant risk of progression to invasive adenocarcinoma, the diagnosis of dysplasia may be challenging.
  • It is expressed in colon adenomas and adenocarcinomas but not in normal colonic epithelium suggesting a role in development of gastrointestinal malignancies.
  • Ninety-six routinely processed biopsy and/or resection specimens (23 negative for dysplasia; 19, low-grade dysplasia; 22, high-grade dysplasia; 16, reactive atypia; and 16, esophageal adenocarcinoma) were immunostained using a monoclonal anti-AMACR antibody p504S.
  • Of 16 specimens, 12 (75%) showed positive staining for AMACR in the adenocarcinoma group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996568.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


89. Kamei Y, Kito K, Takeuchi T, Imai Y, Murase R, Ueda N, Kobayashi N, Abe Y: Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. Hum Pathol; 2007 Aug;38(8):1273-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 50 cases of colorectal adenomas and adenocarcinomas, the accumulation of hScrib protein was commonly observed in comparison with the adjacent normal epithelia.
  • Like beta-catenin, the intense immunoreactivity of hScrib was often observed in small adenomas, thus, suggesting that hScrib could be involved in an early step of colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509663.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


90. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, Marchesi F, Thirunarayanan N, Vischer HF, Qin L, Mayer L, Harpaz N, Leurs R, Furtado GC, Clevers H, Tortorella D, Smit MJ, Lira SA: The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest; 2010 Nov;120(11):3969-78
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VS28 mice showed a hyperplastic intestinal epithelium and, strikingly, developed adenomas and adenocarcinomas by 40 weeks of age.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):741-50 [9049319.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34183-9 [10940307.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1133-7 [11050102.001]
  • [Cites] J Virol. 2001 Jul;75(13):5949-57 [11390596.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Cytokine. 2002 Jul 7;19(1):37-46 [12200112.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1557-63 [12443594.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Pharmacol Ther. 2003 Jun;98(3):269-97 [12782241.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1331-6 [14691920.001]
  • [Cites] Neuropsychopharmacology. 2004 Mar;29(3):441-9 [14628000.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):243-7 [15219948.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):401-8 [9200479.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] J Exp Med. 1998 Sep 7;188(5):855-66 [9730887.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):209-14 [9883886.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:59-88 [9891778.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6476-82 [10037740.001]
  • [Cites] J Gen Virol. 1999 Mar;80 ( Pt 3):543-7 [10091991.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):331-6 [10433925.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):244-9 [15842049.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Int Immunol. 2005 Aug;17(8):1023-34 [16000328.001]
  • [Cites] FEBS J. 2005 Aug;272(16):4163-77 [16098198.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2537-48 [16219459.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jan;27(1):56-63 [16352349.001]
  • [Cites] J Intern Med. 2006 Mar;259(3):219-46 [16476101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73 [16924106.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2295-300 [17035736.001]
  • [Cites] J Neurovirol. 2007;13(1):85; author reply 86-7 [17454453.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1133-9 [17341657.001]
  • [Cites] Nat Protoc. 2007;2(8):1998-2004 [17703211.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):849-64 [18325394.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):83-7 [18488086.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):378-88 [18338378.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):1-9 [19107226.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2861-9 [19318580.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1680-8.e7 [19208363.001]
  • [Cites] Virology. 2009 Sep 15;392(1):1-10 [19720205.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):692-701 [19570946.001]
  • [Cites] Lancet. 1978 May 6;1(8071):957-60 [76890.001]
  • [Cites] Intervirology. 1979;12(2):84-8 [231587.001]
  • [Cites] Intervirology. 1980;14(3-4):223-7 [7239857.001]
  • [Cites] Int J Cancer. 1981 May 15;27(5):659-67 [6270021.001]
  • [Cites] Gut. 1982 Jan;23(1):21-30 [6276266.001]
  • [Cites] Intervirology. 1981;16(4):244-9 [6282775.001]
  • [Cites] Klin Wochenschr. 1985 May 2;63(9):405-8 [2987605.001]
  • [Cites] Gut. 1985 Oct;26(10):1053-8 [2996990.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):741-50 [2836142.001]
  • [Cites] Science. 1990 Feb 2;247(4942):561-4 [1689075.001]
  • [Cites] Cell. 1993 Feb 12;72(3):415-25 [7679328.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28539-42 [7961796.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):40-50 [7806062.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 6;211(1):325-30 [7540006.001]
  • [Cites] J Pathol. 1996 Feb;178(2):201-6 [8683390.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • (PMID = 20978345.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122665002; United States / NIDDK NIH HHS / DK / P01 DK072201; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ORF74 protein, Human herpesvirus 8; 0 / Receptors, Chemokine; 0 / US28 receptor, Cytomegalovirus; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2964974
  •  go-up   go-down


91. Kucherlapati MH, Yang K, Fan K, Kuraguchi M, Sonkin D, Rosulek A, Lipkin M, Bronson RT, Aronow BJ, Kucherlapati R: Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A; 2008 Oct 7;105(40):15493-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large intestinal tumors are predominantly adenomas, whereas the tumors of the small intestine are a mixture of adenomas and adenocarcinomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Aug 28;25(38):5302-8 [16936751.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):638-47 [16258171.001]
  • [Cites] Genome Biol. 2007;8(7):R131 [17615082.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1363-80 [18403596.001]
  • [Cites] PLoS Genet. 2008 Jun;4(6):e1000092 [18551179.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):217-29 [10882064.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6297-302 [11507085.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):751-63 [12198702.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):109-14 [12556968.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1189-95 [15492985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Int J Cancer. 1981 Oct 15;28(4):431-40 [7309289.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Dec;29(2):289-301 [3479234.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Science. 1989 Apr 14;244(4901):207-11 [2565047.001]
  • [Cites] Princess Takamatsu Symp. 1989;20:49-59 [2562187.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1805-15 [10430085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6 [7753829.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3576-83 [16585182.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1061-6 [16570290.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):1-12 [9671308.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1575-81 [9893631.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] FASEB J. 1993 Jul;7(10):931-7 [8344490.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] PLoS Genet. 2006 Sep 15;2(9):e146 [17002498.001]
  • (PMID = 18832169.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084301; United States / NCI NIH HHS / CA / CA-084301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Other-IDs] NLM/ PMC2563082
  •  go-up   go-down


92. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H: Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis; 2009 Jun;24(6):613-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Estrogen receptor alpha (ER alpha), ER beta, AIB1, and TIF2 protein expression were evaluated by immunohistochemistry in colorectal normal mucosa, adenomas, and adenocarcinomas from 110 patients with colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Colorectal Dis. 2009 Dec;24(12):1479 [19479269.001]
  • (PMID = 19198856.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Nuclear Receptor Coactivator 2; 0 / Trans-Activators; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


93. Toth B, Coles M: Inhibition of large intestinal cancers by celecoxib using a serial sacrifice technique. In Vivo; 2006 Jul-Aug;20(4):453-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, the tumors were diagnosed as polypoid adenomas and adenocarcinomas of the cecum, colon and rectum.
  • [MeSH-minor] 1,2-Dimethylhydrazine / administration & dosage. 1,2-Dimethylhydrazine / pharmacology. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Administration, Oral. Animals. Animals, Outbred Strains. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carcinogens / administration & dosage. Carcinogens / pharmacology. Celecoxib. Female. Incidence. Injections, Subcutaneous. Mice. Survival Rate. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900774.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 1R21 AT001739
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; IX068S9745 / 1,2-Dimethylhydrazine; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


94. Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR, Boada LD: Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med; 2005 May;39(5):e27
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature.
  • The misuse of these drugs is associated with serious adverse effects to the liver, including cellular adenomas and adenocarcinomas.
  • We report two very different cases of adult male bodybuilders who developed hepatocellular adenomas following AAS abuse.
  • The second patient was admitted to our hospital with acute renal failure and ultrasound (US) studies showed mild hepatomegaly with several very close hyperecogenic nodules in liver, concordant with adenomas at first diagnosis.
  • The cases presented here are rare but may well be suggestive of the natural course of AAS induced hepatocellular adenomas.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Anabolic Agents / adverse effects. Liver Neoplasms / chemically induced. Methenolone / analogs & derivatives. Nandrolone / analogs & derivatives. Substance-Related Disorders / complications. Testosterone / analogs & derivatives. Testosterone Propionate / analogs & derivatives. Weight Lifting

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. STANOZOLOL .
  • Hazardous Substances Data Bank. OXYMETHOLONE .
  • Hazardous Substances Data Bank. NANDROLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849280.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anabolic Agents; 0SPD480WFH / methenolone enanthate; 3XMK78S47O / Testosterone; 4R1VB9P8V3 / Stanozolol; 5H7I2IP58X / boldenone; 6PG9VR430D / Nandrolone; 7Z6522T8N9 / testosterone enanthate; 8GN84GWX51 / testosterone 17-phenylpropionate; 9062ZT8Q5C / Methenolone; H45187T098 / nandrolone decanoate; L76T0ZCA8K / Oxymetholone; WI93Z9138A / Testosterone Propionate
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC1725213
  •  go-up   go-down


95. Doris K, Karabela SP, Kairi CA, Simoes DC, Roussos C, Zakynthinos SG, Kalomenidis I, Blackwell TS, Stathopoulos GT: Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice. Respir Res; 2010;11:118
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethane resulted in formation of atypical alveolar hyperplasias, adenomas, and adenocarcinomas in mouse lungs.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):139-44 [12957351.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):327-34 [12846363.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Lancet. 2004 Aug 21-27;364(9435):709-21 [15325838.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] J Epidemiol Community Health. 1978 Dec;32(4):303-13 [744822.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Cancer Res. 1992 May 1;52(9 Suppl):2670s-2676s [1562998.001]
  • [Cites] Immunity. 1996 Jan;4(1):15-24 [8574848.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):541-55 [9659582.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1583-4 [9811301.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210 [10413421.001]
  • [Cites] J Asthma. 2005 Sep;42(7):597-600 [16169796.001]
  • [Cites] Cancer Causes Control. 2006 Apr;17(3):349-50 [16489542.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1240-4 [16344268.001]
  • [Cites] J Leukoc Biol. 2006 Jun;79(6):1131-9 [16617160.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Jun 15;173(12):1414-5; author reply 1415 [16760359.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Curr Allergy Asthma Rep. 2007 Jun;7(3):231-6 [17448336.001]
  • [Cites] Nat Med. 2007 May;13(5):570-8 [17435770.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55 [17507545.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Proc Am Thorac Soc. 2007 Oct 1;4(7):512-21 [17878463.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Eur Respir J. 2002 Jan;19(1):127-33 [11843311.001]
  • [Cites] Nat Rev Immunol. 2008 Mar;8(3):218-30 [18274559.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Eur Respir J. 2008 Oct;32(4):1068-81 [18827153.001]
  • [Cites] Nat Med. 2008 Oct;14(10):1023-4 [18841139.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Apr;40(4):443-53 [18927348.001]
  • [Cites] Eur Respir J. 2009 May;33(5):974-85 [19213792.001]
  • [Cites] Am J Respir Crit Care Med. 2009 May 15;179(10):894-902 [19234104.001]
  • [Cites] Arch Intern Med. 2009 Jun 8;169(11):1022-3 [19506169.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):173-4 [19732714.001]
  • [Cites] Nature. 2009 Nov 5;462(7269):104-7 [19847165.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):89-97 [20129250.001]
  • [Cites] Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81 [20595227.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Mol Carcinog. 2003 Nov;38(3):117-23 [14587096.001]
  • (PMID = 20796309.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3IN71E75Z5 / Urethane
  • [Other-IDs] NLM/ PMC2936383
  •  go-up   go-down


96. Noguera Aguilar JF, Amengual Antich I, Plaza Martínez A, Ibarra de la Rosa J, Tortajada Collado C, Gamundí Gamundí A, Pujol Tugores JJ: Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. Rev Esp Enferm Dig; 2005 Sep;97(9):637-47
Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rofecoxib in lower doses had the same effect on adenomas (p < 0.05) with no effect on adenocarcinomas.
  • Rofecoxib reduced COX-2 expression in tumoral tissue from adenomas and adenocarcinomas (p < 0.01).
  • CONCLUSIONS: Rofecoxib prevents chemical colon carcinogenesis in the rat, with a reduction of tumoral colonic percentage in adenocarcinomas and tumoral COX-2 expression.

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266236.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; EC 1.14.99.1 / Cyclooxygenase 2; IX068S9745 / 1,2-Dimethylhydrazine; R16CO5Y76E / Aspirin
  •  go-up   go-down


97. Suzui M, Inamine M, Kaneshiro T, Morioka T, Yoshimi N, Suzuki R, Kohno H, Tanaka T: Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol; 2005 Nov;27(5):1391-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used a long-term rat model by using azoxymethane (AOM) to induce tumors (adenomas and adenocarcinomas) in the colon.
  • In the present study, we found that after AOM injection, the treatment of male F344 rats with 0.01 and 0.05% I3C caused a significant increase in the tumor multiplicity of adenocarcinomas by 2.2- (P<0.05 for 0.01% I3C) and 2.1-fold (P<0.0002 for 0.05% I3C) respectively, when compared to the control rats.
  • In addition, the tumor multiplicity of adenoma plus adenocarcinoma and the volume of adenocarcinoma were also increased by 2.0- (P<0.00001) and 2.1-fold (P<0.05) respectively, compared to the control.
  • I3C significantly increased the proliferating cell nuclear antigen labeling index (PCNA LI) (P<0.008) and decreased the apoptotic index (P<0.05) of the colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Antioxidants / pharmacology. Colonic Neoplasms / pathology. Indoles / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211236.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Indoles; C11E72455F / indole-3-carbinol
  •  go-up   go-down


98. Shi Z, Dragin N, Miller ML, Stringer KF, Johansson E, Chen J, Uno S, Gonzalez FJ, Rubio CA, Nebert DW: Oral benzo[a]pyrene-induced cancer: two distinct types in different target organs depend on the mouse Cyp1 genotype. Int J Cancer; 2010 Nov 15;127(10):2334-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyp1a1(-/-) mice revealed markedly increased CYP1B1 mRNA levels in the PSI, and between 8 and 12 weeks developed unique PSI adenomas and adenocarcinomas.
  • PSI adenocarcinomas exhibited striking upregulation of the Xist gene, suggesting epigenetic silencing of specific genes on the Y-chromosome; the Rab30 oncogene was upregulated; the Nr0b2 tumor suppressor gene was downregulated; paradoxical overexpression of numerous immunoglobulin kappa- and heavy-chain variable genes was found-although the adenocarcinoma showed no immunohistochemical evidence of being lymphatic in origin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • [Cites] Br Med Bull. 2003;68:167-82 [14757716.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1225-37 [15102951.001]
  • [Cites] Biotechniques. 2004 May;36(5):790-6 [15152598.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23847-50 [15028720.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(9):970-8 [15198916.001]
  • [Cites] Mol Pharmacol. 1975 Nov;11(6):850-65 [54870.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2777-83 [679184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5358-61 [281685.001]
  • [Cites] Biochem Pharmacol. 1979;28(1):149-51 [758905.001]
  • [Cites] J Natl Cancer Inst. 1981 May;66(5):913-7 [6262559.001]
  • [Cites] Drug Metab Rev. 1982;13(2):235-47 [6807663.001]
  • [Cites] Pharmacol Rev. 1982 Jun;34(2):189-222 [6287505.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):4875-917 [6814745.001]
  • [Cites] Carcinogenesis. 1983;4(5):513-7 [6850980.001]
  • [Cites] Environ Health Perspect. 1988 Apr;77:11-21 [3289903.001]
  • [Cites] Crit Rev Toxicol. 1989;20(3):153-74 [2558673.001]
  • [Cites] Am J Med. 1992 Jul 15;93(1A):13S-17S [1496998.001]
  • [Cites] Drug Metab Rev. 1994;26(1-2):125-63 [8082562.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):128-9 [8841177.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):117-24 [9472702.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1977-82 [10051580.001]
  • [Cites] Epigenetics. 2008 Sep;3(5):246-9 [19013827.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):607-15 [19001129.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1(6):460-9 [19079213.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36061-5 [18713746.001]
  • [Cites] Hum Genomics. 2008 Sep;3(1):87-97 [19129093.001]
  • [Cites] Bioinformatics. 2009 Jan 15;25(2):211-7 [19038984.001]
  • [Cites] Prog Histochem Cytochem. 2007;42(2):61-110 [17616258.001]
  • [Cites] Surg Today. 2007;37(9):725-34 [17713724.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] APMIS. 2007 Oct;115(10):1147-60 [18042148.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):570-83 [17997381.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2 Suppl):S380-3; quiz S415 [18241686.001]
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] Cancer Sci. 2008 May;99(5):849-55 [18380788.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Biol Chem. 2008 Apr;389(4):323-31 [18225988.001]
  • [Cites] Tissue Antigens. 2008 Jul;72(1):1-10 [18498291.001]
  • [Cites] Hepatology. 2008 Jul;48(1):289-98 [18537191.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1755-61 [18663129.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] Cell Mol Immunol. 2008 Oct;5(5):319-24 [18954554.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2932-8 [16374581.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1103-14 [16377763.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):225-32 [19153668.001]
  • [Cites] Cell Death Differ. 2008 Jul;15(7):1103-12 [18552861.001]
  • [Cites] Biochem Pharmacol. 2000 Jan 1;59(1):65-85 [10605936.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):184-9 [10623596.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Ann N Y Acad Sci. 2000;919:148-70 [11083106.001]
  • [Cites] Drug Metab Rev. 2001 Feb;33(1):1-35 [11270659.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1903-30 [11751421.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2733-40 [12529989.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):368-75 [12584122.001]
  • [Cites] Ind Health. 2003 Jul;41(3):127-38 [12916742.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):199-204 [10102353.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2916-20 [16374579.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1625-32 [16863570.001]
  • [Cites] Exp Anim. 2006 Jul;55(4):343-7 [16880681.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):940-6 [17183066.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):661-3 [16837629.001]
  • (PMID = 20127859.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096-149007; United States / NIEHS NIH HHS / ES / P30 ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-119007; United States / NIEHS NIH HHS / ES / ES014403-03; United States / NIEHS NIH HHS / ES / R01 ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-159007; United States / NIEHS NIH HHS / ES / ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-149007; United States / NIEHS NIH HHS / ES / R01 ES014403; United States / NIEHS NIH HHS / ES / R01 ES014403-04; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R01 ES014403-03S1; United States / NIEHS NIH HHS / ES / ES014403-03S1; United States / NIEHS NIH HHS / ES / P30 ES006096-159007; United States / NIEHS NIH HHS / ES / ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-129007; United States / NIEHS NIH HHS / ES / R01 ES014403-03; United States / NIEHS NIH HHS / ES / P30 ES006096-119007; United States / NIEHS NIH HHS / ES / P30 ES006096-129007; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  • [Other-IDs] NLM/ NIHMS184552; NLM/ PMC2917638
  •  go-up   go-down


99. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • Colonoscopic biopsies have been taken from the lesion in cancer patients, and colonoscopic polypectomy has been performed for adenomas.
  • No significant difference was detected in the comparison of Ki-67 expression levels between the healthy mucosa and adenomas at the patients with cholecystectomy 43,4 +/- 3,45 (p > 0,05), but more prominent increase was revealed in adenocarcinomas 64,33 +/- 7,67% (p < 0,01).
  • At the patients without cholecystectomy the frequency of revealing p53 in adenomas does not vary, compared with healthy mucosa, however in adenocarcinomas p53 was not revealed at none case.
  • As a contrast, in group of the patients with cholecystectomy the frequency of revealing p53 in adenomas is considerably increased (up to 80%), and even in adenocarcinomas, p53 was revealed in 30,8% of cases.
  • At the patients with a cholecystectomy, the increase of proliferative activity is accompanied by increased apoptosis in adenomas and maintained apoptosis in adenocarcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


100. Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart H, Mori H: Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res; 2007 May 1;67(9):4079-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also treated Apc(Min/+) and wild-type mice with N-methyl-N-nitrosourea (MNU), an alkylating agent that induces adenomas and adenocarcinomas in the stomach.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. T Cell Transcription Factor 1 / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483318.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / T Cell Transcription Factor 1; 0 / beta Catenin
  •  go-up   go-down






Advertisement